Wall Street brokerages expect LeMaitre Vascular, Inc. (NASDAQ:LMAT) to report sales of $25.42 million for the current quarter, according to Zacks. Three analysts have made estimates for LeMaitre Vascular’s earnings. The highest sales estimate is $25.45 million and the lowest is $25.40 million. LeMaitre Vascular posted sales of $23.22 million during the same quarter last year, which would indicate a positive year over year growth rate of 9.5%. The company is expected to announce its next quarterly earnings results on Wednesday, October 25th.

On average, analysts expect that LeMaitre Vascular will report full-year sales of $25.42 million for the current financial year, with estimates ranging from $101.91 million to $102.00 million. For the next financial year, analysts forecast that the company will report sales of $110.95 million per share, with estimates ranging from $110.05 million to $112.50 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that follow LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $0.23 EPS for the quarter, beating the consensus estimate of $0.17 by $0.06. The company had revenue of $25.80 million during the quarter, compared to analysts’ expectations of $25.42 million. LeMaitre Vascular had a net margin of 14.19% and a return on equity of 15.02%. LeMaitre Vascular’s revenue for the quarter was up 15.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.14 earnings per share.

LMAT has been the topic of several recent research reports. Zacks Investment Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $38.00 price objective on the stock in a research note on Tuesday, August 1st. Stifel Nicolaus reiterated a “buy” rating and issued a $32.00 price objective (up previously from $29.00) on shares of LeMaitre Vascular in a research note on Sunday, July 30th. Benchmark Co. upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Friday, July 28th. BidaskClub cut shares of LeMaitre Vascular from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Finally, Canaccord Genuity cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating and set a $28.00 target price on the stock. in a research note on Monday, July 10th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $31.60.

ILLEGAL ACTIVITY WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/09/25/25-42-million-in-sales-expected-for-lemaitre-vascular-inc-lmat-this-quarter-2.html.

In other LeMaitre Vascular news, insider David B. Roberts sold 26,683 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $36.67, for a total transaction of $978,465.61. Following the sale, the insider now owns 48,108 shares in the company, valued at approximately $1,764,120.36. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO George W. Lemaitre sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $37.13, for a total transaction of $556,950.00. Following the sale, the chief executive officer now owns 3,325,508 shares in the company, valued at approximately $123,476,112.04. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 373,121 shares of company stock worth $12,825,992. 23.70% of the stock is owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in LMAT. Bank of Montreal Can raised its position in shares of LeMaitre Vascular by 32.2% during the first quarter. Bank of Montreal Can now owns 10,483 shares of the medical instruments supplier’s stock valued at $258,000 after buying an additional 2,552 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of LeMaitre Vascular by 211.2% during the first quarter. Russell Investments Group Ltd. now owns 150,413 shares of the medical instruments supplier’s stock valued at $3,705,000 after buying an additional 102,078 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of LeMaitre Vascular by 33.6% during the first quarter. Wells Fargo & Company MN now owns 130,765 shares of the medical instruments supplier’s stock valued at $3,220,000 after buying an additional 32,910 shares during the last quarter. American Century Companies Inc. raised its position in shares of LeMaitre Vascular by 27.7% during the first quarter. American Century Companies Inc. now owns 192,732 shares of the medical instruments supplier’s stock valued at $4,747,000 after buying an additional 41,848 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of LeMaitre Vascular by 1.6% during the first quarter. Bank of New York Mellon Corp now owns 88,552 shares of the medical instruments supplier’s stock valued at $2,181,000 after buying an additional 1,408 shares during the last quarter. Hedge funds and other institutional investors own 66.32% of the company’s stock.

LeMaitre Vascular (NASDAQ:LMAT) opened at 37.25 on Monday. The company’s 50-day moving average is $35.58 and its 200 day moving average is $29.96. LeMaitre Vascular has a 52 week low of $18.55 and a 52 week high of $39.29. The stock has a market cap of $708.57 million, a PE ratio of 53.21 and a beta of 0.67.

LeMaitre Vascular announced that its board has approved a share repurchase program on Thursday, July 27th that permits the company to buyback $7.50 million in outstanding shares. This buyback authorization permits the medical instruments supplier to reacquire up to 1.4% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s management believes its shares are undervalued.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Wednesday, August 23rd were paid a dividend of $0.055 per share. This represents a $0.22 dividend on an annualized basis and a yield of 0.59%. The ex-dividend date was Monday, August 21st. LeMaitre Vascular’s payout ratio is 31.88%.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.